Tag - BXRX

Developments

FDA approves Baudax Bio’s ANJESO for pain

The FDA approved Baudax Bio’s (NASDAQ:BXRX) ANJESO for the management of moderate-to-severe pain, alone or in combination with other non-NSAID analgesics. ANJESO is a once-daily COX-2 preferential NSAID that is...

February 21, 2020

Markets

Janney starts Baudax Bio at buy; fair value estimate $12

Janney Montgomery Scott launched coverage of Baudax Bio (NASDAQ:BXRX) with a “buy” rating and fair value estimate of $12. The stock closed at $4.51 on Nov. 21. Baudax was spun out of Recro Pharma (NASDAQ:REPH) in a...

November 22, 2019

Tag - BXRX

FDA approves Baudax Bio’s ANJESO for pain

Janney starts Baudax Bio at buy; fair value estimate $12

General

More